Author Affiliations: Massachusetts General Hospital Cancer Center, and Harvard Medical School, Boston, Massachusetts (Dr Zhu); and Memorial Sloan-Kettering Cancer Center, New York, New York (Dr Abou-Alfa).
Hepatocellular carcinoma (HCC) represents a challenging malignancy of worldwide importance: it is the sixth most common cancer and the third most common cause of cancer-related death globally.1 The incidence rates for HCC in the United States and Western Europe have been increasing.2,3 Despite many efforts in prevention and screening for HCC, only 20% to 30% of patients present with early stage disease amenable to curative treatments, including surgical resection and liver transplantation.4,5 Although many interventional-based treatment options are available for unresectable HCC, the benefits and limitations of these individual treatment approaches remain controversial.
Zhu AX, Abou-Alfa GK. Expanding the Treatment Options for Hepatocellular CarcinomaCombining Transarterial Chemoembolization With Radiofrequency Ablation. JAMA. 2008;299(14):1716–1718. doi:10.1001/jama.299.14.1716